Comparative Pharmacology
Head-to-head clinical analysis: ERYGEL versus ERYMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYGEL versus ERYMAX.
ERYGEL vs ERYMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking the translocation of peptidyl-tRNA.
Erythromycin acts by binding to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis. It also acts as a motilin receptor agonist, stimulating gastrointestinal motility.
Apply a thin layer to affected areas twice daily. Topical use only.
250-500 mg orally every 6 hours or 500-1000 mg intravenously every 6 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 1.6 hours (range 1.0–2.5 hours) after topical application, too short to accumulate with daily use.
Terminal elimination half-life: 1.5–2 hours in adults; prolonged to 4–6 hours in hepatic impairment; requires dosing adjustment in cirrhosis.
Primarily hepatic metabolism; less than 10% excreted renally as unchanged drug. Biliary excretion is minimal.
Renal excretion of unchanged drug: 10–15%; biliary/fecal excretion: 85–90% as active metabolites.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic